Some wartime injuries are missed or misdiagnosed. Both veterans and civilians may suffer traumatic brain injury (TBI) and post-traumatic stress disorder (PTSD).
Cohen Veterans Bioscience is focused on improving and detecting TBI, PTSD and related co-morbidities. A test that could detect TBI and PTSD via blood test or MRI would help the affected find appropriate treatment sooner.
For TBI, the Tau protein is a blood marker indicative of degenerative disease. It is relevant in brain anatomy of NFL players. It may be a biomarker of TBI via the blood.
For PTSD, there may be a genetic predisposition or enhanced risk. Most people who are exposed to a single trauma will recover. Only 10-20% will develop PTSD. Perhaps spotting these biomarkers for PTSD vulnerability can lead to enhanced training and preventative training to reduce or eliminate the impact of potential PTSD situations.
Finding the biomarkers and predisposition can help define improved treatment solutions.
Listen as Dr. Magali Haas joins Dr. Susanne Bennett to share the how Cohen Veterans Bioscience is making headway in detecting TBI and PTSD to improve treatment options.